The limited prognostic role of MGMT promoter methylation status despite the broad use of alkylating agents in our patient population was surprising, but may confirm a recent cohort study [25] and is in line with previous data indicating MGMT promoter methylation as a predictive marker of response to alkylating agents in IDH-wildtype glioblastoma but not in IDH-mutant gliomas [53]. The gene discussed is IDH2; the disease is central nervous system cancer.